Table 2.
Investigator-assessed response rates to 2nd-line HL treatment.
| Low risk (N = 36) | High age/comorbidity (N = 33) | Salvage/SC-failure (N = 38) | ASCT with watch&wait (N = 211) | ASCT with RT consolidation (N = 66) | Total (N = 384) | |
|---|---|---|---|---|---|---|
| Response | ||||||
| Missing | 1 | 5 | 9 | 25 | 9 | 49 |
| CR | 26 (74%) | 12 (43%) | 4 (14%) | 133 (72%) | 13 (23%) | 188 (56%) |
| PR | 6 (17%) | 9 (32%) | 4 (14%) | 32 (17%) | 36 (63%) | 87 (26%) |
| SD | 0 (0%) | 2 (7%) | 7 (24%) | 3 (2%) | 4 (7%) | 16 (5%) |
| PD | 3 (9%) | 5 (18%) | 14 (48%) | 18 (10%) | 4 (7%) | 44 (13%) |
SC stem cell harvest, ASCT high-dose chemotherapy and autologous stem-cell transplantation, RT radiotherapy, CR complete remission, PR partial remission, SD stable disease, PD progressive disease.